Dabur Sues Patanjali Over Toothpaste Trade Dress

New Delhi:  Dabur India on Wednesday moved the Delhi High Court alleging that Patanjali Ayurveda’s Dant Kanti Red infringed upon the trade dress of its Red toothpaste with pan flavour.

The court asked Patanjali Ayurved if it could modify the visual appearance of the product. The court posted the matter for further hearing on January 31.

The HC was hearing a suit filed by Dabur seeking a permanent injunction against Patanjali Ayurved, the parent company of Patanjali Foods, for the similarity in trade dress. Dabur said it did not have any grievance over the earlier packaging of Patanjali Ayurved in respect of similar products.

However, it is now becoming difficult to maintain a distinction between the two products due to the similarity in their trade dress, it said. Patanjali Ayurved launched its Dant Kanti Red toothpaste with pan flavour in December.

Related Posts

  • Pharma
  • February 17, 2025
  • 74 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 69 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%